Compare Nuwellis Inc (NUWE) vs Tilray Brands Inc (TLRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuwellis Inc vs Tilray Brands Inc — how do they compare? Nuwellis Inc trades at $0.8 (market cap $2.50M), while Tilray Brands Inc trades at $4.21 (market cap $591.60M). The key difference: Tilray Brands Inc is far larger — about 236.6× Nuwellis Inc's market cap. Which is the better fit depends on your goals.
| NUWE | TLRY | |
|---|---|---|
Market Cap | $2.50M | $591.60M |
Sector | Technology | Health |
52-Week High | $164.50 | $21.00 |
52-Week Low | $0.73 | $3.88 |
Enterprise Value | -$1.21M | $758.73M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $0.7878, up 0.88% today, but remains in a bearish technical trend. The company shows strong gross margins of 69.69% and double-digit revenue growth, but faces significant profitability challenges with negative net income margins and ROE. Recent developments include a reverse stock split, new CEO appointment, and strategic partnerships expanding pediatric care footprint.
While NUWE demonstrates operational progress with revenue growth and margin improvement, persistent losses and negative cash flow present substantial risk. The mixed analyst sentiment and bearish technical indicators suggest cautious approach. Investment appeal hinges on successful execution of financial efficiency strategy and path to profitability.
TLRY trades at $4.30, down 4.44% today, reflecting ongoing investor skepticism despite record fiscal 2026 revenue of $915 million. The stock shows bearish technical signals with key support at $4.00, while fundamentals reveal significant challenges including negative net income margins (-13.26%) and consecutive earnings misses. Recent developments include strategic partnerships expansion in New York and California spirits markets and increased medical cannabis production capacity to 275 metric tonnes.
TLRY faces substantial execution risks with persistent losses and negative cash flow, though trading below book value (P/B 0.37) offers potential value. Analyst consensus remains cautious with 65% hold ratings, while regulatory progress in cannabis remains a key catalyst. The stock requires successful margin improvement and U.S. regulatory clarity for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →
